Request a Quote

Nitrosamine Less-Than-Lifetime Limits: 2026 Guidance Update

Regulatory authorities have formally adopted the ICH M7 less-than-lifetime framework for N-nitrosamine impurities, allowing products with treatment durations under one month to apply an 80-fold multiplier to the nitrosamine acceptable intake. The same update extends the corrective-action transition period from three to seven years for lifelong therapies and adds polymeric IV bags as a recognized nitrosamine risk source requiring extractables and leachables assessment. This guidance on nitrosamine less than lifetime limits reopens limit calculations for short-course products and doubles the compliance window for chronic therapies. The nitrosamine less than lifetime limits framework now applies permanently, not just as a transitional measure.

Why This Update Matters

Since 2018, nitrosamine impurities have forced recalls, disrupted supply chains, and sparked extensive re-evaluation programs across the pharmaceutical industry. Until now, the less-than-lifetime (LTL) exposure concept from ICH M7 -- which permits higher daily intakes for shorter treatment durations -- had not been formally applied to N-nitrosamines. Regulators had previously restricted LTL use to transitional limits during corrective action implementation.

The November 2026 update to the Article 5(3) referral Q&A (Rev.24) changes that. It establishes a structured nitrosamine LTL multipliers table for N-nitrosamines, lengthens the transition window for marketed products exceeding the lifetime acceptable intake, and identifies a new risk vector in polymeric container systems. For manufacturers, the update reopens limit calculations for short-course products, extends compliance timelines for chronic therapies, and expands extractables and leachables testing scope for parenteral products in polymeric packaging. The EU regulatory nitrosamine guidance 2026 marks a significant shift in how lifetime exposure is assessed for these impurities.

Regulatory Framework at a Glance

Element

Previous Position (Rev.23)

Rev.24 Position

LTL framework for N-nitrosamines

Not formally adopted; used only for transitional CAPA limits

Formally adopted per ICH M7 Section 7.3

Nitrosamine LTL multipliers

N/A

1 month or less: 80x AI; more than 1 to 12 months: 30x; more than 1 to 5 years: 10x; more than 5 to 10 years: 3x; more than 10 years to lifetime: 1x

Scope of LTL application

Transitional CAPA limits only

All products with treatment less than lifetime: clinical, marketed, applications

LTL applicability to other N-nitroso structures

Not addressed

Explicitly excluded -- only for N-nitrosamines

CAPA transition period for lifelong products

3 years from initial AI publication

7 years from initial AI publication

Transitional limit (more than 10 years to lifetime)

Not specified

6.7x AI, generally 1.5 ug/day or less (exceptions: AI above 1.5 ug/day, CPCA Category 5, or negative enhanced Ames test)

Transition period anchor date

N/A

Fixed to initial AI publication date; unchanged by later AI revisions

Polymeric IV bags

Not listed as risk source

Listed: nitrosamines observed; low-MW nitrosamines can form from amines/nitrosating agents in monomers, additives, inks; may form during bag making and drug product manufacturing, migrate over time; E&L assessment required

Non-nitrosamine N-nitroso structures

No dedicated guidance

Use Q&A 10 principles: compound-specific data or read-across; CPCA not applicable; standard Ames negative -> 1500 ng/day; unassessed -> 18 ng/day TTC; captured in Appendix 1 "Other N-nitroso structures"

Excipient-sourced nitrosamine limits

General principles

Control strategy + limit must keep patient intake at or below AI; calculate using max daily excipient at max labelled dose; single limit for all strengths unless justified; control point at drug product or excipient level

Multiple nitrosamines (less than 10-year treatment)

Not addressed

Sum of (measured level / LTL-corrected AI of most potent nitrosamine)

Nitrosamine Less Than Lifetime Limits: The Core Change

The centerpiece of Rev.24 is the formal adoption of ICH M7 nitrosamines LTL multipliers for N-nitrosamines. The multipliers reflect the principle that carcinogenic risk correlates with lifetime cumulative dose -- shorter treatment means higher permissible daily intake. Understanding these nitrosamine less than lifetime limits is essential for any manufacturer filing or updating a marketing authorisation in the EU. The nitrosamine AI calculation now incorporates LTL factors directly, simplifying the process for products with treatment durations under one month.

Treatment Duration

LTL Multiplier

Effective Daily Limit

1 month or less

80x

80 x lifetime AI

More than 1 month to 12 months

30x

30 x lifetime AI

More than 1 year to 5 years

10x

10 x lifetime AI

More than 5 years to 10 years

3x

3 x lifetime AI

More than 10 years to lifetime

1x

Lifetime AI (no change)

Applicability conditions:

  • Only for N-nitrosamines (not other N-nitroso structures)
  • Products with treatment duration less than lifetime, including clinical development products, marketed products, and marketing applications
  • Treatment duration classification must align with the approved labelling; rationale should be documented in the submission dossier

Scientific basis: The regulatory assessment cites two publications (Felter and colleagues, Regulatory Toxicology and Pharmacology, 2025 and 2026) that addressed prior concerns: (1) insufficient evidence linking nitrosamine carcinogenic potency to lifetime cumulative dose, (2) concern that short-term high-dose exposure could overwhelm DNA repair capacity, (3) concern about additive exposure from multiple concomitant medications. The publications are said to resolve these points.

Extended Transition Period for Lifelong Therapies

For marketed products on lifelong treatment where nitrosamine levels exceed the lifetime acceptable intake, the corrective action implementation period has been extended from three to seven years. The nitrosamine CAPA transition period now gives manufacturers more time to implement root-cause fixes.

Key parameters:

  • Maximum transition period: 7 years from initial AI publication date
  • Transitional limit: 6.7x AI for products with treatment more than 10 years to lifetime
  • Cap on transitional limit: Generally 1.5 ug/day or less, unless the substance's established AI exceeds 1.5 ug/day, it falls in CPCA Category 5, or the enhanced Ames test is negative
  • Anchor date: The 7-year clock starts at the initial AI publication date and does not reset if the AI is later revised to a stricter value
  • Scope: Applies to marketed lifelong products only; new applications and products under review are not eligible and must engage case-by-case with regulators
  • Products already under stricter transitional limits: Manufacturers may request re-evaluation under the new framework

Operational details carried forward:

  • Transitional limits do not require a variation to be written into the release specification
  • If meeting the transitional limit requires shelf-life or storage condition changes, these must be submitted per the variation classification guideline

Polymeric IV Bags: Newly Recognized Risk Source

Rev.24 adds polymeric infusion bags to the list of identified nitrosamine risk factors under "specific packaging materials," alongside the previously listed nitrocellulose aluminium foil blisters. Polymeric IV bag nitrosamines represent a newly recognized contamination pathway requiring N-nitrosamine risk assessment.

Mechanism described:

  • Nitrosamines have been observed in polymeric bagged injections
  • Low-molecular-weight nitrosamines can form from amines and nitrosating agents present in packaging components -- monomers, plastic additives, printing inks
  • Formation may occur during bag manufacturing and during drug product manufacturing
  • Nitrosamines can migrate into the drug product over time through migration from packaging materials

Regulatory expectation: Extractables and leachables (E&L) studies for polymeric bagged injections should assess nitrosamines and their precursors -- amines and nitrosating agents. Manufacturers should confirm the composition of monomers, additives, and inks with their packaging suppliers.

Implication for exporters: Non-EU manufacturers of injectable products in polymeric packaging, and their packaging suppliers, should anticipate questions on this point in future EU assessments or inspections.

Other N-Nitroso Structures and Excipient-Sourced Nitrosamines

Non-Nitrosamine N-Nitroso Structures (Q&A 23)

The "call for review" three-step process applies only to N-nitrosamines. For other N-nitroso structures identified in drug substance or drug product impurity assessments:

  • Apply Q&A 10 limit-setting principles: compound-specific carcinogenicity data or read-across to a robust surrogate
  • CPCA is not applicable -- it was developed specifically for N-nitrosamines
  • Standard Ames test negative -> 1500 ng/day control
  • The choice between standard Ames and enhanced Ames test should be justified by the mutagenic mechanism
  • No compound-specific AI with adequate justification -> default 18 ng/day TTC (threshold of toxicological concern)
  • Established limits are captured in Appendix 1 under the "Other N-nitroso structures" tab

Excipient-Sourced Nitrosamines (Q&A 10 Amendment)

  • The control strategy and limit must ensure patient daily intake does not exceed the nitrosamine's AI
  • Calculation uses the maximum daily excipient amount at the maximum labelled dose
  • Unless justified, a single limit applies across all strengths
  • The control point may be set at the drug product level or the excipient level
  • If the control point is at the excipient level, other drug product risk factors must first be excluded
  • Drug product nitrosamine testing remains the primary verification method for compliance

Multiple Nitrosamines in Short-Term Products

For products with treatment duration under 10 years where multiple nitrosamines co-exist, the additivity calculation uses the LTL-corrected AI of the most potent nitrosamine. Multiple nitrosamines additivity is now calculated using the LTL-corrected value.

Practical Impact by Product Category

Product Category

Primary Impact

Short-course products (days to weeks): anti-infectives, some oncology, perioperative drugs

Recalculate limits using actual treatment duration via nitrosamine LTL multipliers; previously unachievable NDSRI limits may become feasible

Lifelong / chronic therapies

Nitrosamine transitional limits extended to 7 years from initial AI date; 6.7x AI transitional limit (generally 1.5 ug/day or less); recalculate remaining time from each AI's original publication date

Polymeric IV bags, prefilled syringes, other polymeric container injections

E&L programs must include extractables leachables nitrosamines and precursors (amines, nitrosating agents); engage packaging suppliers on monomer, additive, ink composition; anticipate regulatory scrutiny

Products with non-nitrosamine N-nitroso impurities

Apply Q&A 10 read-across/surrogate approach; CPCA not usable; default 18 ng/day TTC if no compound-specific AI; standard Ames negative -> 1500 ng/day

Counterintuitive Takeaway

The most significant operational change is not the LTL multipliers themselves -- it is that the LTL framework is now permanently available for N-nitrosamines, not just a transitional concession. This means a product with a 14-day treatment course can legitimately use an 80x multiplier in its initial marketing authorisation, not just during a CAPA remediation. The distinction shifts LTL from a "compliance bridge" to a standard limit-setting tool for eligible products. For anyone asking what is the less than lifetime framework for nitrosamines, the answer is now a permanent regulatory tool, not a temporary fix.

Actionable Recommendations

  • Short-course product developers: Re-evaluate NDSRI limit calculation using the LTL multiplier table; document treatment duration classification with labelling alignment in the CMC section
  • Lifecycle teams for chronic products: Map each nitrosamine's initial AI publication date; recalculate remaining transition window under the 7-year rule; assess whether the 6.7x AI transitional limit improves feasibility
  • Parenteral product manufacturers using polymeric packaging: Update E&L protocols to include extractables leachables nitrosamines and precursors (amines, nitrosating agents); request composition declarations from bag/syringe suppliers covering monomers, plastic additives, printing inks
  • Teams assessing non-nitrosamine N-nitroso impurities: Switch from CPCA to read-across/surrogate methodology; prepare justification for Ames vs enhanced Ames test selection; expect 18 ng/day TTC as default
  • Regulatory strategy leads: Note that the 7-year transition anchor date is fixed to initial AI publication -- later AI tightening does not extend the window; plan CAPA completion accordingly
  • Dual-market (EU/US) products: This update reflects the EU regulatory position only; the US regulator and other non-EU regulators' stance on nitrosamine LTL is not aligned in this document -- maintain separate limit strategies per jurisdiction

Limitations

  • This analysis is based on the published Q&A Rev.24 and accompanying Appendix 1 Rev.14; the regulatory web page's "Timely Compliance" section still reflected the 3-year transition as of 7 November 2026 and may be updated subsequently
  • The US regulator and other non-EU regulators' positions on nitrosamine LTL were not verified in the source material
  • The Felter and colleagues publications cited as scientific basis were referenced by the regulatory authority; independent review of those publications was not performed
  • Appendix 1 updates follow a separate rhythm; newly established AIs and "Other N-nitroso structures" limits will continue to appear there

Bottom Line

The November 2026 guidance update makes three material changes: it unlocks the ICH M7 less-than-lifetime framework for routine N-nitrosamine limit setting, it doubles the corrective-action transition window for lifelong therapies to seven years, and it puts polymeric IV bags on the regulatory radar as a nitrosamine risk source requiring dedicated extractables and leachables evaluation. Short-course products gain the most immediate flexibility; chronic products gain time; parenteral manufacturers gain a new testing obligation. Mastering these nitrosamine less than lifetime limits is now critical for EU market access.

FAQ

What is the less-than-lifetime framework for nitrosamines?

The less-than-lifetime framework allows higher acceptable daily intakes for nitrosamine impurities when the treatment duration is shorter than a lifetime, based on the principle that carcinogenic risk correlates with cumulative lifetime dose. This concept, drawn from ICH M7, has now been formally adopted for N-nitrosamines in the November 2026 guidance update.

Which products can use the LTL multipliers?

Products with a treatment duration of less than lifetime -- including clinical development products, marketed products, and marketing applications -- provided the treatment duration classification aligns with the approved labelling and the rationale is documented in the submission.

What are the LTL multipliers for nitrosamines?

Treatment one month or less: 80x AI; more than 1 to 12 months: 30x; more than 1 to 5 years: 10x; more than 5 to 10 years: 3x; more than 10 years to lifetime: 1x (no change from lifetime AI). These multipliers apply only to N-nitrosamines, not to other N-nitroso structures.

Does the LTL framework apply to all N-nitroso compounds?

No. The LTL multipliers apply only to N-nitrosamines. Other N-nitroso structures are explicitly excluded and must use separate limit-setting principles based on compound-specific data or read-across to a robust surrogate, with CPCA not applicable.

How long is the new transition period for lifelong products exceeding the AI?

The transition period is extended to 7 years from the initial AI publication date, up from the previous 3 years. This applies to marketed products on lifelong treatment where nitrosamine levels exceed the lifetime acceptable intake.

What is the transitional limit during the 7-year period?

For products with treatment more than 10 years to lifetime, the transitional limit is 6.7x AI, generally capped at 1.5 ug/day unless the substance's AI exceeds 1.5 ug/day, it is CPCA Category 5, or the enhanced Ames test is negative. The 7-year clock starts at the initial AI publication date and does not reset if the AI is later revised.

Does the 7-year clock reset if the AI is later revised?

No. The anchor date is fixed to the initial AI publication date and does not change even if the AI is subsequently revised to a stricter value. Products already under stricter transitional limits may request re-evaluation under the new framework.

Why are polymeric IV bags now a recognized nitrosamine risk source?

Nitrosamines have been observed in polymeric bagged injections. Low-molecular-weight nitrosamines can form from amines and nitrosating agents in monomers, plastic additives, and printing inks during bag manufacturing and drug product manufacturing, then migrate into the drug product over time. Regulatory expectations now include E&L assessment of these precursors.

What testing is expected for polymeric IV bags?

Extractables and leachables studies should assess nitrosamines and their precursors (amines, nitrosating agents). Manufacturers should confirm monomer, additive, and ink composition with packaging suppliers. Non-EU manufacturers and their suppliers should anticipate questions on this point in future EU assessments or inspections.

How are limits set for non-nitrosamine N-nitroso structures?

Use compound-specific carcinogenicity data or read-across to a robust surrogate. CPCA is not applicable. Standard Ames test negative -> 1500 ng/day. Without adequate justification -> 18 ng/day TTC. Limits are listed in Appendix 1 under "Other N-nitroso structures." The choice between standard Ames and enhanced Ames test should be justified by mutagenic mechanism.

How are excipient-sourced nitrosamine limits calculated?

The control strategy and limit must ensure patient daily intake does not exceed the AI. Calculation uses the maximum daily excipient amount at the maximum labelled dose. A single limit applies to all strengths unless justified. Control point can be at drug product or excipient level; if at excipient level, other drug product risk factors must first be excluded.

How are multiple nitrosamines handled in short-term products?

For products with treatment under 10 years, the additivity calculation uses the LTL-corrected AI of the most potent nitrosamine. This approach applies the LTL multiplier to the most potent nitrosamine's AI before calculating the combined exposure ratio.

Does this guidance apply to the US regulator or other regulators?

No. This update reflects the EU regulatory committee position only. The US regulator and other regulators' stance on nitrosamine LTL is not addressed in this document and should be assessed separately. Manufacturers with dual-market products must maintain separate limit strategies per jurisdiction.

Zhengzhou Minzhong Pharmaceutical Co Ltd | Leading Rifamycin API Manufacturer Since 1994

My Instagram